Japan’s Medinet Commercializes Dendritic Cell Engineering Technology Developed By U.S. Biotech
This article was originally published in PharmAsia News
Executive Summary
Yokohama, Japan-based biomedical company Medinet Aug. 18 began commercializing a dendritic cell engineering technology. Utilizing cell loading technology jointly developed with Gaithersburg, Md.-based MaxCyte, the new approach to cancer immunotherapy is expected to increase efficacy as much as 10 times compared to what Medinet is currently providing. As an immune cell therapy, the efficacy of dendritic cell vaccine therapy is improved when it can take up tumor antigens prepared from the patient's removed tumor, thus inducing more cytotoxic T lymphocytes to attack the patient's tumor cells. (Click here for more - Japanese language